Plasma proteomic analysis of simian immunodeficiency virus infection of rhesus macaques

Journal of Proteome Research

Volumn 9, Issue 9, 2010, Pages 4721-4731

  Wiederin, Jayme L ^a   Donahoe, Robert M ^b   Anderson, James R ^a   Yu, Fang ^a   Fox, Howard S ^a   Gendelman, Howard E ^a   Ciborowski, Pawel S ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

biomarker; iTRAQ; monkey; plasma; proteomics

Indexed keywords

ALPHA2 GLYCOPROTEIN; CERULOPLASMIN; GELSOLIN; GLYCOPROTEIN; HISTIDINE; LEUCINE; LEUCINE RICH ALPHA 2 GLYCOPROTEIN; PLASMA PROTEIN; SERPINA1; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN; VITRONECTIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS INFECTION; VIRUS INFECTION; VIRUS STRAIN;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PROTEINS; BLOTTING, WESTERN; CHROMATOGRAPHY, ION EXCHANGE; ISOTOPE LABELING; MACACA MULATTA; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

MACACA MULATTA; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 77956304903     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr1004345     Document Type: Article

References (66)

1. Pedersen, C. Infection with human immunodeficiency virus type-1. Seroconversion chronic infection and the development of AIDS Dan. Med. Bull. 1994, 41 (1) 12-22
2. Daar, E. S.; Pilcher, C. D.; Hecht, F. M. Clinical presentation and diagnosis of primary HIV-1 infection Curr. Opin. HIV AIDS 2008, 3 (1) 10-5
3. Ford, E. S.; Puronen, C. E.; Sereti, I. Immunopathogenesis of asymptomatic chronic HIV Infection: the calm before the storm Curr. Opin. HIV AIDS 2009, 4 (3) 206-14
4. Mothe, B.; Ibarrondo, J.; Llano, A.; Brander, C. Virological, immune and host genetics markers in the control of HIV infection Dis. Markers 2009, 27 (3) 105-20
5. Roberts, E. S.; Zandonatti, M. A.; Watry, D. D.; Madden, L. J.; Henriksen, S. J.; Taffe, M. A.; Fox, H. S. Induction of pathogenic sets of genes in macrophages and neurons in NeuroAIDS Am. J. Pathol. 2003, 162 (6) 2041-57
6. Fox, H. S.; Gold, L. H.; Henriksen, S. J.; Bloom, F. E. Simian immunodeficiency virus: a model for neuroAIDS Neurobiol. Dis. 1997, 4 (3-4) 265-74
7. Kapadia, F.; Vlahov, D.; Donahoe, R. M.; Friedland, G. The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations Clin. Infect. Dis. 2005, 41 (7) 1027-34
8. Joag, S. V. Primate models of AIDS Microbes Infect. 2000, 2 (2) 223-9
9. Pendyala, G.; Trauger, S. A.; Siuzdak, G.; Fox, H. S. Quantitative plasma proteomic profiling identifies the vitamin E binding protein afamin as a potential pathogenic factor in SIV induced CNS disease J. Proteome Res. 9 (1) 352-8
10. Auer, J.; Camoin, L.; Guillonneau, F.; Rigourd, V.; Chelbi, S. T.; Leduc, M.; Laparre, J.; Mignot, T. M.; Vaiman, D. Serum profile in preeclampsia and intra-uterine growth restriction revealed by iTRAQ technology J. Proteomics 73 (5) 1004-17
11. Kolla, V.; Jeno, P.; Moes, S.; Tercanli, S.; Lapaire, O.; Choolani, M.; Hahn, S. Quantitative proteomics analysis of maternal plasma in Down syndrome pregnancies using isobaric tagging reagent (iTRAQ) J. Biomed. Biotechnol. 2010, 952047
12. Lee, H. J.; Na, K.; Choi, E. Y.; Kim, K. S.; Kim, H.; Paik, Y. K. Simple method for quantitative analysis of N-linked glycoproteins in hepatocellular carcinoma specimens J. Proteome Res. 9 (1) 308-18
13. Latterich, M.; Abramovitz, M.; Leyland-Jones, B. Proteomics: new technologies and clinical applications Eur. J. Cancer 2008, 44 (18) 2737-41
14. Donahoe, R. M.; O'Neil, S. P.; Marsteller, F. A.; Novembre, F. J.; Anderson, D. C.; Lankford-Turner, P.; McClure, H. H. Probable deceleration of progression of Simian AIDS affected by opiate dependency: studies with a rhesus macaque/SIVsmm9 model J. Acquir. Immune Defic. Syndr. 2009, 50 (3) 241-9
15. Akkina, S. K.; Zhang, Y.; Nelsestuen, G. L.; Oetting, W. S.; Ibrahlm, H. N. Temporal stability of the urinary proteome after kidney transplant: more sensitive than protein composition J. Proteome Res. 2009, 8 (1) 94-103
16. Shilov, I. V.; Seymour, S. L.; Patel, A. A.; Loboda, A.; Tang, W. H.; Keating, S. P.; Hunter, C. L.; Nuwaysir, L. M.; Schaeffer, D. A. The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra Mol. Cell. Proteomics 2007, 6 (9) 1638-55
17. Oberg, A. L.; Mahoney, D. W.; Eckel-Passow, J. E.; Malone, C. J.; Wolfinger, R. D.; Hill, E. G.; Cooper, L. T.; Onuma, O. K.; Spiro, C.; Therneau, T. M.; Bergen, H. R., 3rd Statistical analysis of relative labeled mass spectrometry data from complex samples using ANOVA J. Proteome Res. 2008, 7 (1) 225-33
18. Wiederin, J.; Rozek, W.; Duan, F.; Ciborowski, P. Biomarkers of HIV-1 associated dementia: proteomic investigation of sera Proteome Sci. 2009, 7, 8-20
19. Storey, J. D.; Tibshirani, R. Statistical significance for genomewide studies Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (16) 9440-5
20. Krogh, M.; Liu, Y.; Waldemarson, S.; Valastro, B.; James, P. Analysis of DIGE data using a linear mixed model allowing for protein-specific dye effects Proteomics 2007, 7 (23) 4235-44
21. Tonge, R.; Shaw, J.; Middleton, B.; Rowlinson, R.; Rayner, S.; Young, J.; Pognan, F.; Hawkins, E.; Currie, I.; Davison, M. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology Proteomics 2001, 1 (3) 377-96
22. Stephens, A.; Hannan, N. J.; Rainczuk, A.; Meehan, K.; Chen, J. I.; Nicholls, P.; Rombauts, L.; Stanton, P. G.; Robertson, D. M.; Salamonsen, L. Post-Translational Modifications and Protein-Specific Isoforms in Endometriosis Revealed by 2D DIGE J. Proteome Res. 2010, 9, 2438-49
23. Wu, W. W.; Wang, G.; Baek, S. J.; Shen, R. F. Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF J. Proteome Res. 2006, 5 (3) 651-8
24. Chong, P. K.; Gan, C. S.; Pham, T. K.; Wright, P. C. Isobaric tags for relative and absolute quantitation (iTRAQ) reproducibility: Implication of multiple injections J. Proteome Res. 2006, 5 (5) 1232-40
25. Rozek, W.; Horning, J.; Anderson, J.; Ciborowski, P. Sera Proteomic Biomarker Profiling in HIV-1 Infected Subjects with Cognitive Impairment Proteomics-Clin. Appl. 2008, 2, 1498-1507
26. Rozek, W.; Ricardo-Dukelow, M.; Holloway, S.; Gendelman, H. E.; Wojna, V.; Melendez, L.; Ciborowski, P. Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment J. Proteome Res. 2007, 6, 4189-99
27. Pendyala, G.; Trauger, S. A.; Kalisiak, E.; Ellis, R. J.; Siuzdak, G.; Fox, H. S. Cerebrospinal fluid proteomics reveals potential pathogenic changes in the brains of SIV-infected monkeys J. Proteome Res. 2009, 8 (5) 2253-60
28. Ciborowski, P. Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches Biomarkers Med. 2009, 3 (6) 771-785
29. Cordelier, P.; Strayer, D. S. Conditional expression of alpha1-antitrypsin delivered by recombinant SV40 vectors protects lymphocytes against HIV Gene Ther. 2003, 10 (26) 2153-6
30. Cordelier, P.; Strayer, D. S. Mechanisms of alpha1-antitrypsin inhibition of cellular serine proteases and HIV-1 protease that are essential for HIV-1 morphogenesis Biochim. Biophys. Acta 2003, 1638 (3) 197-207
31. Munch, J.; Standker, L.; Adermann, K.; Schulz, A.; Schindler, M.; Chinnadurai, R.; Pohlmann, S.; Chaipan, C.; Biet, T.; Peters, T.; Meyer, B.; Wilhelm, D.; Lu, H.; Jing, W.; Jiang, S.; Forssmann, W. G.; Kirchhoff, F. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide Cell 2007, 129 (2) 263-75
32. Shapiro, L.; Pott, G. B.; Ralston, A. H. Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1 Faseb J. 2001, 15 (1) 115-122
33. Wang, H.; Clouthier, S. G.; Galchev, V.; Misek, D. E.; Duffner, U.; Min, C. K.; Zhao, R.; Tra, J.; Omenn, G. S.; Ferrara, J. L.; Hanash, S. M. Intact-protein-based High-resolution Three-dimensional Quantitative Analysis System for Proteome Profiling of Biological Fluids Mol. Cell. Proteomics 2005, 4 (5) 618-625
34. Okano, T.; Kondo, T.; Kakisaka, T.; Fujii, K.; Yamada, M.; Kato, H.; Nishimura, T.; Gemma, A.; Kudoh, S.; Hirohashi, S. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis Proteomics 2006, 6 (13) 3938-48
35. Shirai, R.; Hirano, F.; Ohkura, N.; Ikeda, K.; Inoue, S. Up-regulation of the expression of leucine-rich alpha(2)-glycoprotein in hepatocytes by the mediators of acute-phase response Biochem. Biophys. Res. Commun. 2009, 382 (4) 776-9
36. Serada, S.; Fujimoto, M.; Ogata, A.; Terabe, F.; Hirano, T.; Iijima, H.; Shinzaki, S.; Nishikawa, T.; Ohkawara, T.; Iwahori, K.; Ohguro, N.; Kishimoto, T.; Naka, T. iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases Ann. Rheum. Dis. 69 (4) 770-4
37. Jones, A. L.; Hulett, M. D.; Parish, C. R. Histidine-rich glycoprotein: A novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems Immunol. Cell Biol. 2005, 83 (2) 106-18
38. Saigo, K.; Yoshida, A.; Ryo, R.; Yamaguchi, N.; Leung, L. L. Histidine-rich glycoprotein as a negative acute phase reactant Am. J. Hematol. 1990, 34 (2) 149-50
39. Jespersen, J.; Gram, J.; Bach, E. A sequential study of plasma histidine-rich glycoprotein and plasminogen in patients with acute myocardial infarction and deep vein thrombosis Thromb. Haemost. 1984, 51 (1) 99-102
40. Morgan, W. T. Serum histidine-rich glycoprotein levels are decreased in acquired immune deficiency syndrome and by steroid therapy Biochem. Med. Metab. Biol. 1986, 36 (2) 210-3
41. Manderson, G. A.; Martin, M.; Onnerfjord, P.; Saxne, T.; Schmidtchen, A.; Mollnes, T. E.; Heinegard, D.; Blom, A. M. Interactions of histidine-rich glycoprotein with immunoglobulins and proteins of the complement system Mol. Immunol. 2009, 46 (16) 3388-98
42. Lafrenie, R. M.; Lee, S. F.; Hewlett, I. K.; Yamada, K. M.; Dhawan, S. Involvement of integrin alphavbeta3 in the pathogenesis of human immunodeficiency virus type 1 infection in monocytes Virology 2002, 297 (1) 31-8
43. Elia, C.; Cassol, E.; Sidenius, N.; Blasi, F.; Castagna, A.; Poli, G.; Alfano, M. Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion J. Leukoc. Biol. 2007, 82 (5) 1212-20
44. Dano, K.; Andreasen, P. A.; Grondahl-Hansen, J.; Kristensen, P.; Nielsen, L. S.; Skriver, L. Plasminogen activators, tissue degradation, and cancer Adv. Cancer Res. 1985, 44, 139-266
45. Blasi, F.; Vassalli, J. D.; Dano, K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors J. Cell Biol. 1987, 104 (4) 801-4
46. Chavakis, T.; Kanse, S. M.; May, A. E.; Preissner, K. T. Haemostatic factors occupy new territory: the role of the urokinase receptor system and kininogen in inflammation Biochem. Soc. Trans. 2002, 30 (2) 168-73
47. Stokol, T.; O'Donnell, P.; Xiao, L.; Knight, S.; Stavrakis, G.; Botto, M.; von Andrian, U. H.; Mayadas, T. N. C1q governs deposition of circulating immune complexes and leukocyte Fcgamma receptors mediate subsequent neutrophil recruitment J. Exp. Med. 2004, 200 (7) 835-46
48. Gutzmer, R.; Lisewski, M.; Zwirner, J.; Mommert, S.; Diesel, C.; Wittmann, M.; Kapp, A.; Werfel, T. Human monocyte-derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons Immunology 2004, 111 (4) 435-43
49. Morgan, B. P.; Marchbank, K. J.; Longhi, M. P.; Harris, C. L.; Gallimore, A. M. Complement: central to innate immunity and bridging to adaptive responses Immunol. Lett. 2005, 97 (2) 171-9
50. Kemper, C.; Atkinson, J. P. T-cell regulation: with complements from innate immunity Nat. Rev. Immunol. 2007, 7 (1) 9-18
51. Carroll, M. C. The complement system in regulation of adaptive immunity Nat. Immunol. 2004, 5 (10) 981-6
52. Villiers, C. L.; Cretin, F.; Lefebvre, N.; Marche, P. N.; Villiers, M. B. A new role for complement C3: regulation of antigen processing through an inhibitory activity Mol. Immunol. 2008, 45 (13) 3509-16
53. Stricker, R. B.; Savely, V. R.; Motanya, N. C.; Giclas, P. C. Complement split products c3a and c4a in chronic lyme disease Scand. J. Immunol. 2009, 69 (1) 64-9
54. Tsuruta, T.; Yamamoto, T.; Matsubara, S.; Nagasawa, S.; Tanase, S.; Tanaka, J.; Takagi, K.; Kambara, T. Novel function of C4a anaphylatoxin. Release from monocytes of protein which inhibits monocyte chemotaxis Am. J. Pathol. 1993, 142 (6) 1848-57
55. Loeffler, D. A.; LeWitt, P. A.; Juneau, P. L.; Sima, A. A.; Nguyen, H. U.; DeMaggio, A. J.; Brickman, C. M.; Brewer, G. J.; Dick, R. D.; Troyer, M. D.; Kanaley, L. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders Brain Res. 1996, 738 (2) 265-74
56. Sundaram, M.; Saghayam, S.; Priya, B.; Venkatesh, K. K.; Balakrishnan, P.; Shankar, E. M.; Murugavel, K. G.; Solomon, S.; Kumarasamy, N. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India Int. J. Infect. Dis. 2008, 12 (6 e61-6
57. Spinardi, L.; Witke, W. Gelsolin and diseases Subcell. Biochem. 2007, 45, 55-69
58. Wagner, M. Growth factor control of autophagy Nat. Cell Biol. 2005, 7 (3) 212
59. Bruder, C.; Hagleitner, M.; Darlington, G.; Mohsenipour, I.; Wurzner, R.; Hollmuller, I.; Stoiber, H.; Lass-Florl, C.; Dierich, M. P.; Speth, C. HIV-1 induces complement factor C3 synthesis in astrocytes and neurons by modulation of promoter activity Mol. Immunol. 2004, 40 (13) 949-61
60. Pendyala, G.; Fox, H. S. Proteomic and metabolomic strategies to investigate HIV-associated neurocognitive disorders Genome Med. 2007, 3, 22
61. Stoiber, H.; Soederholm, A.; Wilflingseder, D.; Gusenbauer, S.; Hildgartner, A.; Dierich, M. P. Complement and antibodies: a dangerous liaison in HIV infection? Vaccine 2008, 26 (Suppl 8 I79-85
62. Rearden, A.; Hurford, R.; Luu, N.; Kieu, E.; Sandoval, M.; Perez-Liz, G.; Del Valle, L.; Powell, H.; Langford, T. D. Novel expression of PINCH in the central nervous system and its potential as a biomarker for human immunodeficiency virus-associated neurodegeneration J. Neurosci. Res. 2008, 86 (11) 2535-42
63. Congote, L. F. The C-terminal 26-residue peptide of serpin A1 is an inhibitor of HIV-1 Biochem. Biophys. Res. Commun. 2006, 343 (2) 617-22
64. Weivoda, S.; Andersen, J. D.; Skogen, A.; Schlievert, P. M.; Fontana, D.; Schacker, T.; Tuite, P.; Dubinsky, J. M.; Jemmerson, R. ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand J. Immunol. Methods 2008, 336 (1) 22-9
65. Alfano, M.; Sidenius, N.; Blasi, F.; Poli, G. The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection J. Leukoc. Biol. 2003, 74 (5) 750-6
66. Sporer, B.; Koedel, U.; Popp, B.; Paul, R.; Pfister, H. W. Evaluation of cerebrospinal fluid uPA, PAI-1, and soluble uPAR levels in HIV-infected patients J. Neuroimmunol. 2005, 163 (1-2) 190-4